[Blood coagulation/fibrinolytic disorders in diabetic patients].
In many diabetic patients, disturbances of components of the coagulation/fibrinolysis system have been observed. These disturbances have been studied extensively due to their interrelations with the development of atherosclerotic vascular lesions. A thrombophilia (increased tendency to form thrombi) is regarded as a part of the presently widely discussed Metabolic Syndrome. In diabetic patients, increases of the fibrinogen concentration, of the factor VII activity and of the von Willebrand factor, of the concentration and activity of the plasminogen activator inhibitor as well as a raised platelet reactivity have been measured. Probably, further disturbances exist in the complexly regulated subsystems of hemostasis. Not only the hyperglycemia, but also dyslipidemias and a number of other factors do modify the individual situation. First of all, the therapeutic approach to reduce the atherosclerotic risk in the diabetic patients focuses on the optimization of these factors. In this context, a fat-modified diet, physical activity and eumetabolisation in a broader sense are especially important. In high-risk patients, especially within the framework of the secondary prevention of atherosclerotic lesions, the use of fibrates and of inhibitors of platelet aggregation are to be taken into consideration.
Julius
U
U
Abteilung Klinische Stoffwechselforschung, Medizinischen Fakultät der Technischen Universität Dresden.
D001780:Blood Coagulation Tests; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003925:Diabetic Angiopathies / Q000097:blood* / Q000401:mortality; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013927:Thrombosis / Q000097:blood*
Gerinnungs-/Fibrinolysestörungen bei Diabetikern.